These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11249036

  • 1. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
    Czuczman MS, Grillo-López AJ, McLaughlin P, White CA, Saleh M, Gordon L, LoBuglio AF, Rosenberg J, Alkuzweny B, Maloney D.
    Ann Oncol; 2001 Jan; 12(1):109-14. PubMed ID: 11249036
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.
    J Clin Oncol; 2001 Jan 15; 19(2):389-97. PubMed ID: 11208830
    [Abstract] [Full Text] [Related]

  • 4. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
    Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E.
    Leuk Res; 2006 Dec 15; 30(12):1563-8. PubMed ID: 16530831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K.
    Neoplasma; 2001 Dec 15; 48(6):501-5. PubMed ID: 11949845
    [Abstract] [Full Text] [Related]

  • 8. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
    Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R.
    Blood; 2002 Feb 01; 99(3):856-62. PubMed ID: 11806987
    [Abstract] [Full Text] [Related]

  • 9. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
    Martin S, Fischer C, Free M, Kurreck B, Stockinger H, Fenk R, Arnold C, Kliszewski S, Meckenstock G, Haas R, Kronenwett R.
    Eur J Haematol; 2005 Apr 01; 74(4):282-92. PubMed ID: 15777339
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Follicular lymphoma: 2012 update on diagnosis and management.
    Freedman A.
    Am J Hematol; 2012 Oct 01; 87(10):988-95. PubMed ID: 23001911
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.
    Leuk Lymphoma; 2006 Jun 01; 47(6):1041-7. PubMed ID: 16840195
    [Abstract] [Full Text] [Related]

  • 13. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P.
    Leuk Lymphoma; 2006 Jul 01; 47(7):1306-14. PubMed ID: 16923561
    [Abstract] [Full Text] [Related]

  • 14. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
    Léonard BM, Hétu F, Busque L, Gyger M, Bélanger R, Perreault C, Roy DC.
    Blood; 1998 Jan 01; 91(1):331-9. PubMed ID: 9414302
    [Abstract] [Full Text] [Related]

  • 15. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
    Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R.
    Blood; 2005 May 01; 105(9):3428-33. PubMed ID: 15637137
    [Abstract] [Full Text] [Related]

  • 16. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ.
    J Clin Oncol; 2004 Dec 01; 22(23):4711-6. PubMed ID: 15483015
    [Abstract] [Full Text] [Related]

  • 17. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
    Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E.
    Br J Haematol; 2002 Jan 01; 116(1):229-35. PubMed ID: 11841421
    [Abstract] [Full Text] [Related]

  • 18. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
    Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG.
    Exp Hematol; 2002 Jul 01; 30(7):703-10. PubMed ID: 12135667
    [Abstract] [Full Text] [Related]

  • 19. Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21).
    Ha CS, Lee MS, McLaughlin P, Tucker SL, Wilder RB, Cox JD, Cabanillas F.
    Cancer J; 2004 Jul 01; 10(1):49-53. PubMed ID: 15000495
    [Abstract] [Full Text] [Related]

  • 20. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.